Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Acorda’s R&D efforts are designed to:

  • Determine if dalfampridine is a therapeutic option for people with post-stroke walking deficits
  • Develop CVT-301 as a potential treatment for OFF episodes in people with Parkinson’s disease
  • Assess the potential of PLUMIAZ® as a treatment for people with epilepsy who experience cluster seizures
  • Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS
  • Further clinical development of cimaglermin (GGF2) for the treatment of people with heart failure; Acorda is also interested in studying cimaglermin as a potential treatment in several neurological applications
  • Advance other clinical and preclinical stage products in our pipeline, which have potential therapeutic value in neurological conditions such as MS, spinal cord injury, stroke, and traumatic brain injury
Click on AMPYRA, ZANAFLEX, or QUTENZA for Indication and Important Safety Information. Click on a compound in development for more information.
Therapy Phase 1 Phase 2 Phase 3 Marketed
AMPYRA® (dalfampridine)
Walking in MS
 
 
 
 
ZANAFLEX® (tizanidine HCI)
Spasticity
 
 
 
 
QUTENZA® (capsaicin)
Post-Shingles
Nerve Pain
 
 
 
 
DALFAMPRIDINE
Chronic Post-Stroke Walking Deficits
 
 
 
 
CVT-301
Parkinson's Disease
 
 
 
 
PLUMIAZ
Cluster Seizures
 
 
 
 
CIMAGLERMIN ALFA
Heart Failure
 
 
 
 
rHlgM22
MS
 
 
 
 
CVT-427
Migraine
Migraine